دورية أكاديمية

Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma

التفاصيل البيبلوغرافية
العنوان: Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma
المؤلفون: Wang HH, Zaorsky NG, Meng MB, Wu ZQ, Zeng XL, Jiang B, Jiang C, Zhao LJ, Yuan ZY, Wang P
المصدر: OncoTargets and Therapy, Vol 2015, Iss default, Pp 437-444 (2015)
بيانات النشر: Dove Medical Press, 2015.
سنة النشر: 2015
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Huan-Huan Wang,1,* Nicholas G Zaorsky,2,* Mao-Bin Meng,1 Zhi-Qiang Wu,1 Xian-Liang Zeng,1 Bo Jiang,1 Chao Jiang,1 Lu-Jun Zhao,1 Zhi-Yong Yuan,1 Ping Wang1 1Department of Radiation Oncology, CyberKnife Center, and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People’s Republic of China; 2Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA *These authors contributed equally to this work Background and aim: Limited-stage combined small cell esophageal carcinoma (LS-C-SCEC) is a rare, poorly understood, underdiagnosed disease, with components of both small cell esophageal cancer and non–small cell esophageal cancer. We investigated the optimal treatment strategy and prognostic factors in patients with LS-C-SCEC. Patients and methods: LS-C-SCEC patients included in the analysis (from our hospital and the literature) were treated between January 1966 and December 2013. Patient treatment strategies included surgery (S), chemotherapy (CT), and radiation therapy (RT). The primary end point was overall survival (OS); the secondary end points included tumor complete response rates, patterns of failure, and toxicity. Kaplan–Meier curves were compared with the log-rank test. Univariate and multivariate analyses were used to determine prognosticators for OS. Results: A total of 72 patients were included in the analysis: 24 (33%) from our hospital and 48 (67%) from the literature. The median OS of all patients was 15.0 months. Patients who received CT had a significantly longer median OS than did those who did not (OS 22.8 months vs 10.0 months) (P=0.03). Patients treated with multimodality therapy (including RT+CT [18%], S+CT [40%], or S+RT+CT [17%]) vs monotherapy (typically, S [18%]) had significantly improved OS (15.5 months vs 9.3 months) (P=0.02) and complete response rates. On multivariate analysis, tumor location (upper third of the esophagus) and type of treatment (monotherapy) were the only factors predictive of poor OS. Conclusion: Multimodality therapy (including RT+CT, S+CT, or S+RT+CT) improves OS for patients with LS-C-SCEC compared with monotherapy (typically, S). Additional studies are necessary to personalize multimodal treatment approaches to individual patients. Keywords: esophageal neoplasm, small cell, radiation therapy, surgery, chemotherapy
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1178-6930
Relation: http://www.dovepress.com/multimodality-therapy-is-recommended-for-limited-stage-combined-small--peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
URL الوصول: https://doaj.org/article/f06ebe3af37845388492bca457114a6c
رقم الأكسشن: edsdoj.f06ebe3af37845388492bca457114a6c
قاعدة البيانات: Directory of Open Access Journals